Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome
NCT01652326
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
either
1. a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs;
2. > 40mg of diazepam (or diazepam equivalents) in 1 hr; or
3. an individual dose of 40 mg or greater of intravenous diazepam for control of agitation
- if < 18 years of age or had evidence of use of other illicit substances as determined
by urine toxicology screen
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Pittsburgh, Pennsylvania
| Descriptive Information | |||
|---|---|---|---|
| Brief Title | Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome | ||
| Official Title | Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome | ||
| Brief Summary | The overarching goal of this project is to improve the clinical quality of patients with Benzodiazepine-resistant alcohol withdrawal syndrome. | ||
| Detailed Description | Not Provided | ||
| Study Type | Observational | ||
| Study Design | Observational Model: Cohort Time Perspective: Retrospective | ||
| Target Follow-Up Duration | Not Provided | ||
| Biospecimen | Not Provided | ||
| Sampling Method | Non-Probability Sample | ||
| Study Population | hospitalized inpatients | ||
| Condition | Alcohol Withdrawal Syndrome | ||
| Intervention | Drug: Diazepam | ||
| Study Groups/Cohorts | Benzodiazepine-resistant
those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) >40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation Intervention: Drug: Diazepam | ||
| Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||
| Recruitment Information | |||
| Recruitment Status | Completed | ||
| Actual Enrollment | 792 | ||
| Original Estimated Enrollment | 1000 | ||
| Actual Study Completion Date | September 2015 | ||
| Actual Primary Completion Date | September 2015 (Final data collection date for primary outcome measure) | ||
| Eligibility Criteria | Inclusion Criteria: either
Exclusion Criteria:
| ||
| Sex/Gender |
| ||
| Ages | 18 Years and older (Adult, Older Adult) | ||
| Accepts Healthy Volunteers | No | ||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||
| Listed Location Countries | United States | ||
| Removed Location Countries | |||
| Administrative Information | |||
| NCT Number | NCT01652326 | ||
| Other Study ID Numbers | UPittsburgh 0031860 | ||
| Has Data Monitoring Committee | No | ||
| U.S. FDA-regulated Product | Not Provided | ||
| IPD Sharing Statement | Not Provided | ||
| Responsible Party | University of Pittsburgh | ||
| Study Sponsor | University of Pittsburgh | ||
| Collaborators | Hospira, now a wholly owned subsidiary of Pfizer | ||
| Investigators | Not Provided | ||
| PRS Account | University of Pittsburgh | ||
| Verification Date | January 2016 | ||